BioWorld

Oct. 29, 2007

While RA Bids Line Runway, Poll Finds Unhappy Patients

The phrase "rheumatoid arthritis" almost right away calls to mind Genentech Inc.'s Rituxan (rituximab, which targets the CD20 antigen, for RA and non-Hodgkin's lymphoma). (BioWorld Financial Watch) Read More

Money Raised By Month

Stock Winners and Losers For The Week

Collaborations Between Biotechnology Companies And Government/Nonprofit Institutions: Aug. 31 - Oct. 18, 2007

BioWorld Stock Report For Public Biotechnology Companies

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 12, 2025

At CROI, HIV cure trials raise hopes for broader applicability

BioWorld

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...

Hummingbird migrates ADCs, tech to newco Callio’s $187M debut

BioWorld

Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...